Description
Adverse Drug Reactions Journal (药物不良反应杂志, ADRJ) is an academic journal issued domestically and internationally, which is sponsored by Chinese Medical Association and supervised by China Association for Science and Technology. It was founded in 1999 and published monthly, ISSN was 1008-5734. Its founder was professor Cheng Jinghua (程经华), who was the major pioneer and initiator of the monitoring work on adverse drug reactions in China. The idea of the journal is to run its own characteristics, make its best products, strive for its fame, and go to the world. Professor Li Lin, the current editor-in-chief, is the chief expert of the Pharmaceutical Department of Xuanwu Hospital, Capital Medical University, the vice president of the Chinese Pharmacological Association, the president of the Beijing Pharmacological Association, etc. He has served as the vice president of Xuanwu Hospital of Capital Medical University, the director of the Pharmaceutical Research Office, the deputy director of the National Clinical Research Institute of Drugs, the executive deputy director of the Key Laboratory of Neurodegenerative Diseases of the Ministry of Education, and the director of the Beijing Neuropharmaceutical Engineering and Technology Research Center. The journal has a sound editorial committee with consultants such as academician of Chinese Academy of Sciences, professor Chen Keji (陈可翼), and academician of Chinese Academy of Engineering, professor Gao Runlin (高润霖), Ning Guang (宁光), and Zhong Nanshan (钟南山). Editorial members come from 28 provinces, autonomous regions, municipalities directly under the Central Government, the United States and Singapore, covering clinical medicine (cardiovascular, respiratory, gastroenterology, nephrology, neurology, psychiatry. endocrinology, rheumatology, hematology, infectious diseases, oncology, allergy, dermatology, ophthalmology, etc.), pharmacology (clinical pharmacy, clinical pharmacology, pharmaceutics, pharmacoeconomics, pharmacy administration, etc.), nursing, clinical toxicology, pharmaceutical epidemiology, evidence-based medicine, statistics, and other disciplines.
ADRJ focuses on the release of academic achievements in adverse drug events (adverse drug reactions, medication errors and drug quality defects), drug-induced diseases, and medication safety. The aims of the journal are to promote communication of drug safety information through reporting adverse drug reactions and their occurrence rules, improve clinical safe drug use level, protect public drug use safety and serve public health. The main columns include editorial, forum, original article, review, practice and research on clinical medication safety, pharmacist case record, case report, poisoning treatment, adverse reaction of traditional Chinese medicine, and historical story of drug accident, etc. Referring to the Reactions Weekly, ADRJ takes timely reporting new and serious adverse drug events as its feature. Among the reported adverse drug reactions, there is the first case reported globally or nationally. For example, the rhabdomyolysis induced by telbivudine published in 2009, which is the first case in the world, and the infliximab-induced aplastic anemia published in 2012, which is the first case in China and the second case in the world.
ADRJ is a peer-reviewed journal and insists on the quality first of the manuscript. The journal follows relevant national standards and Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals.
At present, ADRJ is the statistical source journal of “Chinese Science and Technology Paper Citation Database (CSTPCD)”, the source journal of “Chinese Science Citation Database (CSCD)” and is indexed by Ulrich's Periodicals Directory and International Pharmaceutical Abstract. In January 2020, ADRJ was officially included in Scopus, which is owned by Elsevier B.V. and is the largest peer-reviewed literature abstract and citation database in the world. The Scopus Content Selection & Advisory Board (CSAB) evaluate the journal as follows: Timely and accurate drug reaction reporting has global significance. The Chinese experience in this field is thus hugely important, particularly given the scale of the Chinese population and the reach of the Chinese pharmaceutical industry. It raises the journal directly from national to global importance. The journal has been recognized by the important international retrieval system, and the internationalization process of the journal has made great progress.
Because the contents inosculate closely to the clinic with strong technicality and practicability, the issue of the journal not only covers in 34 provinces, autonomous regions and municipalities across the country, including Hong Kong, Macao and Taiwan, but also in the United States, the United Kingdom, Germany, France, Australia, New Zealand, Japan, South Korea, Singapore, Malaysia, and other countries. The fruitful work since its inception has established its academic status in the field of adverse drug reaction monitoring and medication safety in China. In September 2012, the National Health and Family Planning Commission decided to set up a clinical medication safety group under the INRUD China Central Group and establish a clinical medication safety monitoring network. The relevant work was entrusted to adverse drug reactions Journal Agency.
To better implement the aims of the journal, various forms of academic activities were also held, including the China Forum on Drug-induced Diseases and Medication Safety, the hot topic discussion on medication safety, the difficult case discussion, the special academic seminar, the adverse drug reaction monitoring training course, etc. The China Forum on Drug-induced Diseases and Medication Safety has become an important distinguished academic meeting about clinical drug safety application, which has been held annually since 2009. The Adverse Drug Reaction Journal will, as always, adhere to the aims of running the magazine, never forget the original intention and forge ahead!
Address: Room 1089, Teaching Building, Xuanwu Hospital, Capital Medical University, Donghuajinzuo, No.118, Guang’anmennei Street, Xicheng District, Beijing 100053, China
Post code: 100053
Website: www.cadrj.com
备案号: 11010502037788, 京ICP备10218182号-8)